Multiple Myeloma

The expert panel discusses factors that influence referral to transplant as well as selecting maintenance and consolidation therapies for patients with multiple myeloma.

Key opinion leaders in the field of multiple myeloma review data looking at patient outcomes in the GRIFFIN and MASTER trials based on cytogenetic abnormalities.

Michael Rosenzweig, MD, MS, presents the clinical scenario of a 68-year-old man with transplant-ineligible newly diagnosed multiple myeloma to the expert panel for discussion.

Natasha Garg, DO, MS, and Neel Talwar, MD, explain the resources they utilize at City of Hope for treating patients with high-risk newly diagnosed multiple myeloma.

Investigators report that patients with relapsed/refractory myeloma treated with mezigdomide and dexamethasone primarily experienced myelotoxic effects.

A detailed overview of therapeutic options for patients undergoing treatment for newly diagnosed multiple myeloma.

A panel of experts on multiple myeloma discuss the decision to refer patients with newly diagnosed multiple myeloma for transplant.

A panel of experts from City of Hope and satellite clinics review the available frontline therapy options for patients with transplant-eligible newly diagnosed multiple myeloma.

Michael Rosenzweig, MD, MS, presents the clinical scenario of a 61-year-old woman with transplant-eligible newly diagnosed multiple myeloma to the panel for discussion.

Findings from the phase 1/2 MajesTEC-1 study support the European Commission’s approval of teclistamab at a reduced dose frequency for patients with relapsed/refractory multiple myeloma.

At an Around the Practice, experts from Emory University gathered to discuss treatment options for patients with multiple myeloma who are transplant-eligible or ineligible.

Experts in the field of multiple myeloma highlight key takeaways for clinicans to be aware of for infections associated with bispecific antibody multiple myeloma treatments.

The FDA allows for expanded bridging therapies in addition to other trial protocol amendments to enable investigators to continue their evaluation of CART-ddBCMA in relapsed/refractory multiple myeloma.

Saad. Z. Usmani, MD, leads a panel of experts in discussing toxicities associated with treatment for multiple myeloma.

In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.

Expert Wilson Gonsalves, MD, shares clinical data in multiple myeloma centered on the distinction between biochemical versus clinical progression.

Elranatamab-bcmm is now approved for patients with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Covering the first of two abstracts, Wilson Gonsalves, MD, reviews data from the IKEMA study of isatuximab KD in patients with relapsed/refractory multiple myeloma.

Panelists from both the Mayo Clinic and UT Southwestern comment on data from ALLIANCE A061202 and consider the role of isatuximab in patients with relapsed/refractory multiple myeloma.

Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.

Adeel Khan, MD, MPH, MS, expert in multiple myeloma management, reviews data from the ALLIANCE A061202 trial of isatuximab + pomalidomide + dexamethasone in relapsed/refractory disease.

The expert panel overviews factors to consider with bispecific antibodies and offers closing insights on unmet needs in the multiple myeloma treatment space.

Experts from the Mayo Clinic and UT Southwestern share insight on the CARTITUDE-4 study and ciltacabtagene autoleucel in the second cross Q&A session.

Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, share closing thoughts on the evolving landscape of cytokine release syndrome management in relapsed/refractory multiple myeloma.

Closing out their program on relapsed/refractory multiple myeloma, Ajai Chari, MD, and Carolina Schinke, MD, consider optimal treatment strategies in the current landscape and look toward future directions in care.

Experts in the multiple myeloma space discuss recent developments and how to implement new practices in real-world settings.

Key opinion leader Prashant Kapoor, MD, FACP, shares data from the CARTITUDE-4 study of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Nausheen Ahmed, MD, gives an overview of BCMA bispecific T-cell engagers used in the treatment of multiple myeloma.

Panelists follow up with questions and comments on the KarMMa-3 study in relapsed/refractory multiple myeloma and consider how idecabtagene vicleucel might fit into real-world practice.

Following their review of data from MajesTEC-1, panelists consider how they manage patients with cytokine release syndrome in the real-world setting.